Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Journal of Virology|August 13, 2024
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designsZekun Mu, Jill Whitley, Diana Martik, et al.
Journal of Virology|March 9, 2018
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization EscapeLingshu Wang, Wei Shi, James D Chappell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2026
Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V<sub>H</sub>1-2-rearranging mouse modelsHimanshu Batra, Sai Luo, Kevin O Saunders, et al.
Cell Reports|March 16, 2022
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in miceZekun Mu, Kevin Wiehe, Kevin O Saunders, et al.
NPJ Vaccines|April 10, 2021
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
Plos Pathogens|September 19, 2019
Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodiesCelia C LaBranche, Rory Henderson, Allen Hsu, et al.
Cell Reports|February 6, 2020
Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope ImmunizationQifeng Han, Todd Bradley, Wilton B Williams, et al.
Plos Pathogens|December 3, 2019
Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodiesCelia C LaBranche, Rory Henderson, Allen Hsu, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|December 6, 2021
Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trialsJill Whitley, Christopher Zwolinski, Christian Denis, et al.
Science Translational Medicine|January 8, 2025
An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutationsOlivia M Swanson, Qianyi E Zhang, Elizabeth Van Itallie, et al.
Pageof 15